Making implant removal easier


RemovAid CEO featured in The Journal of the Norwegian Medical Association

RemovAid founder and CEO, Marte Bratlie, explains how her physician background serves her well also as an entrepreneur in a recent video interview with the Norwegian Medical Association. Despite veering from the traditional path for young doctors, she is still driven by a wish to improve people's health while simultaneously exploring her own curiosity. 


Increased awareness of contraceptive implant benefits needed among general practitioners
A new student report from the University of Oslo, Faculty of Medicine concludes that norwegian GPs are underprescribing contraceptive implants and other LARC methods. The report emphasizes the need for initiatives to raise awareness of contraceptive implants in general practice to align with recommendations from the Directorate of Health, advocating the use of LARC as preferred methods of birth control
Read more

Norwegian organizations' commitment to global health

A Government report, presenting Norwegian efforts to improve Global health, was issued today by the Ministries of Foreign Affairs and Health and Care Services. The report highlights improvement of women's and children's rights and health as one of three focus areas for Norwegian Global health policy toward 2020. Minister of International Development, Mr. Holmås, demonstrated, with assistance of RemovAid CEO Marte Bratlie, insertion of a subdermal contraceptive implant as an important means to improve women's health and autonomy.
Read more

UN recommends contraceptive implants for family planning in third world
Norwegian PM Jens Stoltenberg and Nigerian president Goodluck Jonathan delivers report to UN Secretary-General Ban Ki-moon on 13 recommended medications and medical products on behalf of the UN Commission on Life-Saving Commodities for Women and Children, among which are contraceptive implants.
Read more

Contraceptive implants to become available for 27 million women and children in low-income countries
A new partnership announced today at the United Nations will make contraceptive implants available to more than 27 million women in the world's poorest nations. Under the agreement, German pharmaceutical firm Bayer HealthCare AG is halving the price of its long-acting, reversible method of contraception, Jadelle, in return for a commitment to assure funding for at least 27 million contraceptive devices over the next six years. The agreement will be effective starting January 2013.
Read more

Long-acting reversible contraception is superior to other contraceptive methods

A recent publication in the New England Journal of Medicine demonstrates that the effectiveness of LARC is superior to that of contraceptive pills, patch, or ring and is not dependent on age of the user. The contraceptive failure rate among participants using pills, patch, or ring was 4.55 per 100 participant-years, as compared with 0.27 among participants using LARC.
Read more

RemovAid News 

RemovAid publishes first article
In collaboration with authors from the University of Oslo and the youth sexual health clinic Sex og Samfunn, we have investigated use of long-acting reversible contraception among Norwegian adolescents. We conclude that use is still low and that increased awareness and dispelling of myths among health care professionals and adolescent women may improve the uptake of these methods. Read more


RemovAid project receives funding from the Research Council of Norway and the Bill & Melinda Gates Foundation
RemovAid has initiated a major R&D project that aims to improve access to complete family planning services and reversible contraception by development and clinical testing of a device to facilitate safe removal of sub dermal contraceptive implants by mid- and lower-level health workers in low and middle income countries. The project is a collaboration between RemovAid, US based nonprofit human development organization FHI360, UK based reproductive health care provider Marie Stopes International and Swedish medical university Karolinska Institutet. The project is supported by the Research Council of Norway and the Bill & Melinda Gates Foundation.

RemovAid relocates to Oslo Science Park
This August RemovAid has moved into new offices in Oslo Science Park, centrally located only 10 minutes from Oslo city center, between the campuses of the University of Oslo and Oslo University Hospital. The facility currently houses more than 160 companies and research organizations. 
How to get here

From concept to company: The first year of business

Marte Bratlie presenting RemovAid research at ESC World Congress 2013 in Copenhagen
In a new feature interview RemovAid CEO Marte Bratlie talks in detail about experiences and achievements within the first year of business. Only one year ago she launched her own company based on an innovative idea; today she has a patent pending prototype.

Read more  

Marte Bratlie awarded prestigious MedTech award

RemovAid CEO, Marte Bratlie (center), was awarded first prize at the annual Inven2 MedTech awards. Among 26 contributions the jury unanimously selected Ms Bratlie's "Medical device to simplify and standardise surgical procedure" as the worthy recipient of the NOK100000 prize. Inven2 is a TTO owned by the University of Oslo and Oslo University Hospital.

RemovAid qualifies for Regional Research Funding
The Regional Research Funds, established in 2010 as a new funding system in addition to the national funding system, aim to increase R&D efforts in all Norwegian regions. A number of companies have used the regional funding possibility as a starting point for their research-based innovation process.

Innovation Norway supports RemovAid business start-up
Innovation Norway, the Norwegian Government´s most important instrument for innovation and development of Norwegian enterprises and industry, has granted RemovAid funding for business establishment. 

RemovAid becomes Oslo Medtech member
Oslo Medtech is a Norwegian Medtech cluster of companies, hospitals, finance-, knowledge and research institutions focusing on medical technology. Oslo Medtech generates innovation and facilitates development of medtech products and services.

RemovAid receives R&D funding from the Research Council of Norway
RemovAid project "Improving the quality of reproductive health services - Simplifying and standardizing the contraceptive implant removal procedure" is granted funding through Oslo Medtech and The Research Council of Norway´s Programme for Regional R&D and Innovation (VRI).


Company Address
Gaustadalléen 21
0349  OSLO

Visiting Address
Oslo Science Park
Gaustadalléen 21
0349  OSLO

Website Builder